| Description |
1 online resource (xvi, 335 pages) : illustrations |
| Bibliography |
Includes bibliographical references (pages 291-326) and index. |
| Contents |
Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured -- film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Ineffective. inferior or needlessly costly new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. |
|
Can there be too much of a good thing? the hazards of uncritically embracing medical advances -- What's the problem? don't we need lifesaving new treatments? -- Medical innovations and American culture: the call of the sirens -- Why more isn't always better: red herrings, side effects, and superbugs -- Why newer isn't always better: unpleasant surprises, recalls, and learning curves -- Social hazards: what we lose by uncritical use of new treatments -- How things really work: opinion makers and regulators of medical advances -- What will you swallow? how drug companies get you to buy more expensive drugs than you may need -- Making friends, playing monopoly, and dirty tricks: other industry strategies -- Stacking the deck? how to get the "right" answer in clinical research -- "Cancer cured -- film at 11:00": the media's role in disseminating medical advances -- Doctors and hospitals: fueling the drive for new and more -- Advocacy groups: Mother Teresa's waiting room -- Holes in the safety net: the FDA and the FTC -- Useless, harmful, or marginal: popular treatments that caused unnecessary disability, dollar costs, or death -- Ineffective or inferior new drugs -- Medical devices that disappoint -- Ineffective or needlessly extensive surgery -- Weight loss technology: shedding pounds from your waistline or your wallet? -- Crossing the threshold: improving the transition from "experimental" to "standard care" -- For doctors: evidence-based medicine -- For insurers and researchers: pay now or pay more later -- For all decision makers: getting value for money -- For government: regulatory approaches to improve the dissemination of medical innovations -- For consumers: shared decision making. |
| Note |
Print version record. |
| Summary |
Annotation Medical science has always promised -- and often delivered -- a longer, better life. But as the pace of science accelerates, do our expectations become unreasonable, fueled by an industry bent on profits and a media desperate for big news?Hope or Hype is a taboo-shattering look at what drives the American obsession with medical "miracles," exposing the equipment manufacturers and pharmaceutical companies; doctors and hospitals too quick to order surgery; the politicians; the press; and our own "technoconsumption" mindset. The authors spread blame for the parade of so-called miracle cures that too often are marginally effective at best -- and sometimes downright dangerous. They examine consumers? eager embrace of medical advances, and present riveting stories of the conscientious doctors and researchers who blew the whistle on ineffective treatments. Finally, they provide sane, practical recommendations for the adoption of new developments. The consequences of questionable practices include costly recalls, billions in wasted money, and the pain and suffering of innumerable patients and their families. In short, they must stop. |
| Subject |
Medical innovations -- United States -- Evaluation.
|
|
Medical technology -- United States -- Evaluation.
|
|
Medical care -- Technological innovations -- United States -- Evaluation.
|
|
Medical care -- United States -- Evaluation.
|
|
Medical innovations -- Economic aspects -- United States.
|
|
Medical technology -- United States -- Cost effectiveness.
|
|
Medical care -- Technological innovations -- United States -- Cost effectiveness.
|
|
Medical care, Cost of -- United States.
|
|
TECHNOLOGY & ENGINEERING -- Biomedical.
|
|
MEDICAL -- Family & General Practice.
|
|
MEDICAL -- Allied Health Services -- Medical Technology.
|
|
MEDICAL -- Biotechnology.
|
|
MEDICAL -- Lasers in Medicine.
|
| Indexed Term |
Andre fag (naturvidenskab og teknik) Andre fag |
| Added Author |
Patrick, Donald L.
|
| Other Form: |
Print version: Deyo, Richard A. Hope or hype. New York : AMACOM, American Management Association, ©2005 0814408451 (DLC) 2004022295 (OCoLC)56591961 |
| ISBN |
0814428592 (electronic bk.) |
|
9780814428597 (electronic bk.) |
|
